The expression and concentration of CD40 ligand in normal pregnancy and pre-eclampsia. 2009

D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
Department of Obstetrics and Perinatology, Medical University of Lublin, Lublin, Poland. dorotak@mp.pl

This study investigated the surface expression of the CD154 antigen (CD40L) on peripheral blood CD4+ T lymphocytes and the sera concentrations of soluble CD40L antigens (sCD40L) in non-pregnant women, normal pregnant women, and patients with pre-eclampsia. Twenty-five patients with pre-eclampsia, 18 healthy pregnant women, and 10 healthy non-pregnant women were included in the study. The expression of the CD154 antigen on CD4+ T lymphocytes was determined using flow cytometry. The serum concentration of sCD40L was measured using an ELISA. Statistical analysis was performed using the Mann-Whitney U and ANOVA tests. The expression of the CD154 antigen on CD4+ T lymphocytes and the serum concentration of soluble CD40L were significantly higher in pre-eclampsia than in normal pregnant women. In normal pregnancy the expression of the CD154 antigen on CD4+ T lymphocytes and the concentration of sCD40L were significantly lower than in non-pregnant women. We conclude that during normal pregnancy the levels of these inflammatory mediators are lower than in non-pregnant women. In pre-eclampsia the levels are higher than those in normal pregnancy, but stable compared with the non-pregnant state. These results suggest that in pre-eclampsia, there are disturbances in the mechanisms responsible for the decrease in innate immunity which occurs in normal pregnancy.

UI MeSH Term Description Entries
D011225 Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease. Toxemias, Pregnancy,EPH Complex,EPH Gestosis,EPH Toxemias,Edema-Proteinuria-Hypertension Gestosis,Gestosis, EPH,Hypertension-Edema-Proteinuria Gestosis,Preeclampsia,Preeclampsia Eclampsia 1,Pregnancy Toxemias,Proteinuria-Edema-Hypertension Gestosis,Toxemia Of Pregnancy,1, Preeclampsia Eclampsia,1s, Preeclampsia Eclampsia,EPH Toxemia,Eclampsia 1, Preeclampsia,Eclampsia 1s, Preeclampsia,Edema Proteinuria Hypertension Gestosis,Gestosis, Edema-Proteinuria-Hypertension,Gestosis, Hypertension-Edema-Proteinuria,Gestosis, Proteinuria-Edema-Hypertension,Hypertension Edema Proteinuria Gestosis,Of Pregnancies, Toxemia,Of Pregnancy, Toxemia,Pre Eclampsia,Preeclampsia Eclampsia 1s,Pregnancies, Toxemia Of,Pregnancy Toxemia,Pregnancy, Toxemia Of,Proteinuria Edema Hypertension Gestosis,Toxemia Of Pregnancies,Toxemia, EPH,Toxemia, Pregnancy,Toxemias, EPH
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D006262 Health The state of the organism when it functions optimally without evidence of disease. Individual Health,Normalcy,Normality,Health, Individual,Normalcies,Normalities
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D023201 CD40 Ligand A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1. Antigens, CD154,CD154 Antigens,Tumor Necrosis Factor Ligand Superfamily Member 5,Antigen, CD154,CD154 Antigen,CD40L,T-B Cell Activating Molecule,TNF Superfamily, Member 5,gp39 Antigen, T-Cell,T-Cell gp39 Antigen,gp39 Antigen, T Cell

Related Publications

D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
June 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
January 1987, Acta obstetricia et gynecologica Scandinavica,
D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
October 1958, Lancet (London, England),
D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
November 1972, American journal of obstetrics and gynecology,
D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
June 2010, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
May 1996, Reviews of reproduction,
D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
February 2004, BJOG : an international journal of obstetrics and gynaecology,
D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
February 2004, BJOG : an international journal of obstetrics and gynaecology,
D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
February 2004, BJOG : an international journal of obstetrics and gynaecology,
D Darmochwal-Kolarz, and B Kolarz, and A Surdacka, and J Rolinski, and B Leszczynska-Gorzelak, and J Oleszczuk
February 2004, BJOG : an international journal of obstetrics and gynaecology,
Copied contents to your clipboard!